Ann: R&D Tax Incentive rebate received of $4.58 million, page-2

ASX ANNOUNCEMENT
R&D Tax Incentive rebate received of $4.58 million Actinogen receives R&D Tax incentive rebate of $4.58 million Further strengthens Company’s financial position Rebate in line with expectations and follows the recent positive XanaHES trial resultsSydney 24 October 2019: Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) today received an R&D Tax Incentive rebate of $4.58 million for the financial year 2018/2019. The rebate amount was in line with expectations as a first rebate, for FY2019. A further rebate of approximately $0.65 million is expected later this year.The receipt of this rebate comes as the Company is diligently reviewing the totality of the XanaHES study results and those from other Xanamem trials, to optimally shape the future clinical development program of Xanamem, its lead candidate.Actinogen CEO and Managing Director Dr Bill Ketelbey noted that “while the Company is fully funded for its existing and ongoing studies, the tax rebate helps bolster our financial position.”“Our focus in the months ahead is on completing the ongoing Xanamem studies, and determining how best these results, along with the breakthrough XanaHES results announced previously, best shape Xanamem’s future clinical development program. We look forward to updating the market and shareholders on this progress in the near future,” said Dr Ketelbey. Actinogen MedicalDr. Bill KetelbeyCEO & Managing DirectorP: +61 2 8964 7401E: [email protected]@BillKetelbeyAbout Actinogen MedicalENDSInvestor and Media EnquiriesArthur ChanWE BuchanM: +61 2 9237 2805E: [email protected]